Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation Controversies and Advances 2025

Cuffless blood pressure devices: Are they ready for prime time?

Presenter: Jennifer L. Cluett

January 30, 2025

Presentation TCT 2024

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

Presenter: Roland Schmieder

October 28, 2024

Presentation TCT 2024

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

Presenter: Karl Fengler

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Presenter: Ron miller

October 25, 2023

Presentation TCT 2023

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Presenter: Karl Fengler

October 25, 2023

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation TCT 2021

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Presenter: Daniel Burkhoff

November 05, 2021

Presentation TCT 2021

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Presenter: Victor Zeijen

November 04, 2021

Presentation TCT 2021

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Presenter: Daniel Burkhoff

November 04, 2021

Presentation TCT 2021

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

Presenter: Herbert D. Aronow

November 04, 2021

Presentation TCT 2019

The Essentials of Blood Pressure Measurement: Office, Home, and Ambulatory — And Why It Matters

Presenter: Michael Weber

September 28, 2019

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation

Differential Blood Pressure Effects of Ibuprofen, Naproxen, and Celecoxib in Patients with Arthritis

August 30, 2017

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Advertisement

Cuffless blood pressure devices: Are they ready for prime time?

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

The Essentials of Blood Pressure Measurement: Office, Home, and Ambulatory — And Why It Matters

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Differential Blood Pressure Effects of Ibuprofen, Naproxen, and Celecoxib in Patients with Arthritis

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content